What are the recommended antibiotics for acute infectious colitis in adults based on the likely bacterial or parasitic pathogen?

Antibiotic Selection for Colitis: A Pathogen-Specific Approach

The choice of antibiotics for colitis depends entirely on the underlying etiology—for Clostridioides difficile infection (CDI), use oral vancomycin 125 mg four times daily for severe disease or oral metronidazole 500 mg three times daily for non-severe disease; for acute infectious bacterial colitis with dysentery, use azithromycin 1000 mg as a single dose for empiric coverage of invasive pathogens; and for ulcerative colitis, antibiotics are generally not recommended as they provide no benefit.

Clostridioides difficile Colitis

Initial Episode Treatment

For non-severe CDI (stool frequency <4 times daily, no signs of severe colitis):

• Oral metronidazole 500 mg three times daily for 10 days 1

For severe CDI (fever >38.5°C, WBC >15×10⁹/L, hemodynamic instability, peritoneal signs, or colonic distension):

• Oral vancomycin 125 mg four times daily for 10 days 1
• Consider increasing vancomycin to 500 mg four times daily in life-threatening cases 2
• Fidaxomicin 200 mg twice daily for 10 days is an alternative with lower recurrence rates, though not superior for PCR ribotype 027 2

When Oral Therapy Is Impossible

For non-severe disease:

• IV metronidazole 500 mg three times daily for 10 days 1

For severe disease:

• IV metronidazole 500 mg three times daily PLUS intracolonic vancomycin 500 mg in 100 mL normal saline every 4-12 hours and/or vancomycin 500 mg four times daily via nasogastric tube 1

Recurrent CDI

For second and subsequent recurrences:

• Oral vancomycin 125 mg four times daily for at least 10 days, followed by either a taper regimen (decreasing daily dose by 125 mg every 3 days) or pulse strategy (125 mg every 3 days for 3 weeks) 1
• Fidaxomicin 200 mg twice daily for 10 days is preferred for recurrent disease 2
• Fecal microbiota transplantation combined with antibiotics is strongly recommended for multiple recurrences unresponsive to repeated antibiotic treatment 2

Critical Pitfalls in CDI Management

• Never use oral metronidazole for severe or life-threatening CDI—it is strongly discouraged due to inferior outcomes 2
• Avoid antiperistaltic agents and opiates as they increase risk of toxic megacolon 1
• Consider colectomy before serum lactate exceeds 5.0 mmol/L in patients with toxic megacolon, perforation, or deteriorating condition despite antibiotics 1, 2, 1

Acute Infectious Bacterial Colitis

Empiric Treatment for Febrile Dysentery

When invasive bacterial pathogens (Shigella, Salmonella, Campylobacter) are suspected based on fever and bloody diarrhea:

• Azithromycin 1000 mg as a single oral dose 3

This provides coverage for the most common invasive enteropathogens while minimizing resistance concerns compared to fluoroquinolones 3.

Pathogen-Specific Treatment

For confirmed Shigella infections:

• Sulfamethoxazole-trimethoprim is the Access antibiotic of choice if susceptible 4
• β-lactams appear more effective than fluoroquinolones when 90% of cases have confirmed Shigella (RR 4.68 for persistent diarrhea with fluoroquinolones) 4
• Azithromycin, ceftriaxone, or nalidixic acid are alternatives 4

For cholera:

• Doxycycline or tetracycline, or a single dose of a fluoroquinolone 4
• Azithromycin (single dose) reduces diarrhea duration by 32.4 hours compared to ciprofloxacin 4

For non-typhoidal Salmonella:

• Antibiotics are NOT routinely recommended for uncomplicated cases 4
• Use antibiotics only for severe infection, age <6 months or >50 years, or patients with prostheses, valvular heart disease, severe atherosclerosis, malignancy, or uremia 4
• Options include sulfamethoxazole-trimethoprim (if susceptible), fluoroquinolone, ceftriaxone, or azithromycin 4

For Campylobacter:

• Note increasing fluoroquinolone resistance; avoid fluoroquinolones if recent quinolone exposure within 3 months 4

Critical Considerations for Bacterial Colitis

• Do NOT use antibiotics for Shiga toxin-producing E. coli (STEC) infections due to increased risk of hemolytic uremic syndrome 4
• Fluoroquinolones should only be used if hospital surveys indicate ≥90% susceptibility of E. coli to quinolones 5
• Standard stool culture should be performed to guide pathogen-specific therapy 3, 6
• Multiplex PCR followed by guided culture on PCR-positive pathogens is the preferred diagnostic approach 7

Inflammatory Bowel Disease (Ulcerative Colitis and Crohn's Disease)

Ulcerative Colitis

No antibiotic regimen can be recommended for ulcerative colitis, neither for active disease (including acute severe colitis) nor for maintenance of remission 8.

The evidence shows:

• Single-agent antibiotics (tobramycin, amoxicillin-clavulanate, ciprofloxacin, rifaximin, vancomycin, metronidazole) have failed to show useful effects 8
• Combination antibiotic regimens show marginal statistical benefit but lack clinical significance 8
• Ciprofloxacin and metronidazole were ineffective as adjuncts in acute severe colitis 8

Crohn's Disease

Metronidazole 10-20 mg/kg/day has demonstrated effectiveness but is not recommended as first-line therapy due to potential side effects 9. It has a role in:

• Selected patients with colonic or treatment-resistant disease 9
• Patients who wish to avoid steroids 9
• Concomitant use with IV steroids when distinguishing active disease from septic complications is difficult 9

Pouchitis (Post-Colectomy for UC)

For acute pouchitis:

• Ciprofloxacin is the first-choice antibiotic 8
• Metronidazole is an alternative 8

For chronic resistant pouchitis:

• No antibiotic regimen can currently be recommended 8

Complicated Intra-Abdominal Infections (Including Colonic Perforation)

For community-acquired infections of mild-to-moderate severity involving the colon:

Single-agent options:

• Ticarcillin-clavulanate, cefoxitin, ertapenem, moxifloxacin, or tigecycline 5

Combination regimens:

• Metronidazole PLUS cefazolin, cefuroxime, ceftriaxone, cefotaxime, levofloxacin, or ciprofloxacin 5

Key Requirements for Colonic Infections

• Coverage for enteric gram-negative aerobic and facultative bacilli AND enteric gram-positive streptococci is mandatory 5
• Obligate anaerobic coverage (including Bacteroides fragilis) is essential for colon-derived infections 5
• Empiric enterococcal coverage is NOT necessary 5
• Empiric antifungal therapy for Candida is NOT recommended 5

Agents to Avoid

• Ampicillin-sulbactam: High resistance rates among community-acquired E. coli 5
• Cefotetan and clindamycin: Increasing resistance among Bacteroides fragilis group 5
• Aminoglycosides: Not recommended for routine use due to toxicity 5